Verastem (VSTM) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

VSTM Verastem

Watchlist

3.9200
+0.1600+4.26%

Close Nov 1 16:00 ET

3.9099
-0.0101-0.26%

Post 20:02 ET

157.76MMarket Cap-1221P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Verastem Oncology Completes Rolling NDA Submission To The FDA For Avutometinib Plus Defactinib As A Treatment For Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer; Seeking Accelerated Approval And Priority Review Of Its NDA Submission In Patients...
BenzingaOct 31 16:14 ET
Express News | Verastem Inc - FDA Filing Decision Expected Before End of 2024 With Potential for FDA Approval Decision by Mid-2025
ReutersOct 31 16:01 ET
Express News | Verastem Oncology Completes Rolling Nda Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent Kras Mutant Low-Grade Serous Ovarian Cancer
ReutersOct 31 16:01 ET
Verastem Oncology to Participate in Upcoming Investor Conferences
BusinesswireOct 31 07:30 ET
Optimistic Buy Rating: Strong Phase 2 Results and Regulatory Progress for Verastem's Avutometinib and Defactinib
TipRanksOct 21 08:48 ET · Ratings
Verastem Price Target Maintained With a $13.00/Share by RBC Capital
Dow JonesOct 18 10:02 ET · Ratings

Comments

Tonyco

Yesterday 11:49

$Verastem (VSTM.US)$
Pretty damn good run so far. I only managed to hop on in Sept.

Jaguar8

Yesterday 04:01

NEWS

$Verastem (VSTM.US)$
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
Verastem Oncology (VSTM) has completed its rolling New Drug Application (NDA) to the FDA for avutometinib plus defactinibcombination therapy for adults with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC). The company is seeking accelerated approval and priority review, with a potential FDA ap...